Table 3. Stratification analysis of the association between lncRNA polymorphisms and overall toxicity.
| Gene | SNP | Subgroup | Additive |
Dominant |
Recessive |
|||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |||
| ANRIL | rs1333049 | More 57a | 0.559 (0.357, 0.875) | 0.011* | 0.473 (0.243, 0.920) | 0.027* | 0.475 (0.220, 1.025) | 0.058 |
| NSCLC | 0.681 (0.489, 0.948) | 0.023* | 0.578 (0.349, 0.959) | 0.034* | 0.667 (0.386, 1.151) | 0.146 | ||
| Advanced NSCLC | 0.715 (0.521, 0.982) | 0.038* | 0.675 (0.416, 1.097) | 0.112 | 0.615 (0.359, 1.054) | 0.077 | ||
| PS 1 | 0.680 (0.491, 0.940) | 0.020* | 0.570 (0.347, 0.937) | 0.027* | 0.656 (0.382, 1.127) | 0.126 | ||
| rs10120688 | NSCLC | 1.142 (0.809, 1.612) | 0.450 | 0.899 (0.563, 1.435) | 0.656 | 2.308 (1.126, 4.734) | 0.022* | |
| H19 | rs2107425 | Less 57b | 0.871 (0.561, 1.368) | 0.543 | 1.200 (0.660, 2.181) | 0.550 | 0.367 (0.138, 0.976) | 0.045* |
| ADC | 0.734 (0.452, 1.195) | 0.214 | 0.955 (0.498, 1.831) | 0.889 | 0.232 (0.063, 0.853) | 0.029* | ||
| SCLC | 2.185 (0.886, 5.385) | 0.089 | 4.152 (1.134, 15.200) | 0.032* | 1.263 (0.236, 6.745) | 0.785 | ||
| EP | 2.100 (0.892, 4.943) | 0.089 | 4.239 (1.245, 14.430) | 0.020* | 0.993 (0.201, 4.899) | 0.993 | ||
| HOTAIR | rs7958904 | NSCLC | 0.779 (0.544, 1.116) | 0.173 | 0.914 (0.586, 1.425) | 0.690 | 0.333 (0.121, 0.915) | 0.033* |
| Advanced NSCLC | 0.804 (0.568, 1.136) | 0.216 | 0.931 (0.609, 1.422) | 0.740 | 0.306 (0.110, 0.854) | 0.024* | ||
| PS 1 | 0.634 (0.443, 0.907) | 0.013* | 0.621 (0.402, 0.958) | 0.031* | 1.350 (0.173, 10.530) | 0.775 | ||
Abbreviations: SNP, single nucleotide polymorphism; OR, odd ratio; CI, confidence interval; NSCLC, non-small-cell lung cancer; ADC, adenocarcinoma; SCLC, small-cell lung cancer; EP, platinum+etoposide; PS, performance score. More 57a=age more 57. Less 57b=age less 57.
*P<0.05.